Halobetasol
ULTRAVATE
What it isSuperpotent topical corticosteroid; psoriasis and severe dermatoses.
Why this oneAmong the strongest topical steroids, clearing plaques weaker agents cannot.
What limits itSkin atrophy and axis suppression over large areas. Two weeks at a time, off the face and flexures.
FDA-approved for
- plaque psoriasis and corticosteroid-responsive dermatoses
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Corticosteroid-responsive dermatoses | Adults | Thin layer QD-BID | Thin layer QD-BID | ≤50 g/week; limit to 2 weeks |
Renal Undefined
Hepatic Undefined
Instructions
- Apply a thin layer and rub in gently and completely
- Limit treatment to 2 weeks; do not exceed 50 g/week
- Do not use with occlusive dressings
- Discontinue when control achieved; reassess if no improvement in 2 weeks
Cautions
- Super-high potency topical corticosteroid — limit duration and amount
- Local reactions: skin atrophy, telangiectasia, striae, hypopigmentation
- Systemic HPA-axis effects possible with excessive/prolonged use
Adverse reactions
- Stinging or burning
- Pustulation, erythema
- Skin atrophy, telangiectasia
- Leukoderma, acne, itching
- Secondary infection, dry skin
Pregnancy Category C; teratogenic in animals; use only if potential benefit justifies risk to fetus
Lactation Undefined
NO BOXED WARNINGS
Principal riskSkin atrophy; axis suppression over large areas
Cost, est. cash$10–$300/month
Generic entry2004
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityLocal tissue effects and irritation; systemic corticosteroid toxicity is uncommon at usual exposure.
Mechanism of action: Halobetasol ballicule
